Cancer Policy FDA advances rare disease drug development with new evidence principles September 12, 2025Vol.51 No.33By Jacquelyn Cobb
Drugs & Targets FDA approves gemcitabine intravesical system for non-muscle invasive bladder cancer September 12, 2025Vol.51 No.33
Drugs & Targets FDA grants Hernexeo Breakthrough Therapy designation as first line use for HER2-mutant advanced NSCLC September 12, 2025Vol.51 No.33
Drugs & Targets FDA seeks academic and patient advocate research partners for oncology data analysis September 12, 2025Vol.51 No.33
Cancer Policy The departure (and return) of Vinay Prasad September 05, 2025Vol.51 No.32By Claire Marie Porter
Cancer Policy Trump administration wants to rebuild stockpile of APIs to address drug shortages September 05, 2025Vol.51 No.32By Sara Willa Ernst
Cancer Policy FDA will speed up public release of Complete Response Letters September 05, 2025Vol.51 No.32By Sara Willa Ernst
Drugs & Targets FDA approves expanded indication for Avtozma intravenous formulation in cytokine release syndrome September 05, 2025Vol.51 No.32
Drugs & Targets FDA grants breakthrough designation for Rina-S in advanced endometrial cancer September 05, 2025Vol.51 No.32
